… N.V. entered into a research collaboration to apply the Axiomer ® RNA editing technology to fibrosis targets selected … research collaboration with Galapagos, where the company’s Axiomer ® technology will be applied to certain fibrosis … partnering and other strategic relationships for the Axiomer ® platform in select therapeutic areas Entered into a …
… Scientific Officer role, with leadership oversight of Axiomer ® RNA-editing platform technology John Maraganore, … to provide strategic oversight of ProQR’s proprietary Axiomer RNA-editing platform technology. He is the scientific … new strategy, including further building out the Company’s Axiomer RNA-editing technology as a value-generating …
… X: Late-breaking clinical studies Poster presentation on Axiomer ® RNA editing technology A presentation will be … PhD, Sr. scientist computational analytics of ProQR on the Axiomer ® RNA editing technology. Poster title: … Western world have LCA10 because of this mutation. About Axiomer ® Technology Platform ProQR is pioneering a …
… our earlier-stage pipeline candidates, and to advance our Axiomer ® and Trident ™ RNA-editing technology platforms.” … through intravitreal injections in the eye. About Axiomer and Trident ProQR is pioneering a next-generation RNA … yield a new class of medicines for genetic diseases. Axiomer “Editing Oligonucleotides”, or EONs, mediate single …
… EST This presentation will highlight ProQR’s proprietary Axiomer ® platform, a fully owned and in house developed RNA … in the retina with oligonucleotide therapeutics. About Axiomer ® platform technology ProQR is pioneering a next-generation RNA technology called Axiomer ® , which could potentially yield a new class of …
… based on novel RNA editing technologies including our Axiomer ® technology." Dr. Yu is a professor of biochemistry … that do not currently have treatment options." About Axiomer ® Technology Platform ProQR is pioneering a next-generation RNA technology called Axiomer ® , which could potentially yield a new class of …
… in patients with LCA10 and preclinical data for ProQR’s Axiomer ® RNA-editing technology. Abstract titles: ○ … through intravitreal injections in the eye. About Axiomer ® Technology Platform ProQR is pioneering a next-generation RNA technology called Axiomer ® , which could potentially yield a new class of …
… into other forms of genetic blindness Validate and expand Axiomer ® : Further validate and expand ProQR's proprietary Axiomer ® RNA editing platform through first development … QR-1123, QR-421a, QR-411a, QR-504, the potential of our Axiomer ® editing platform, our plans and timing of …